Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

Institut Paoli-Calmettes becomes first RayStation

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
Posted On: 10/10/2013 3:45:09 AM
Avatar
Posted By: News Desk 2018
Institut Paoli-Calmettes becomes first RayStation® reference clinic in France

RaySearch Laboratories AB has received an order for its RayStation® treatment planning system from Institut Paoli-Calmettes (IPC) in Marseille, France. IPC is a French regional comprehensive cancer center that serves the Provence -Alpes-Côte d’Azur and Corsica region. The center offers all forms of cancer therapy and is also conducting extensive research programs. The hospital has over 1,300 employees and treats around 7,000 new cancer patients annually. IPC will use RayStation® as its treatment planning system for conventional 3D-CRT treatments, as well as more advanced treatments, such as IMRT and VMAT. The order also includes sophisticated solutions, such as multi-criteria optimization, enabling a more efficient treatment planning process. Multi -criteria optimization is a highly intuitive tool that lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming plan optimization process. In addition, IPC will function as a reference clinic for RayStation® meaning that RaySearch will be able to bring potential customers to the clinic to see the system in clinical practice and undergo training. The institute will also have access to research versions of RayStation® that contain all of the latest advanced RayStation® tools that can be evaluated and used in the institute’s research programs. “RayStation® is the state-of-the-art in treatment planning today so it stood out as the best solution for us. RaySearch also has a very strong development team and we appreciate that we will be able to work with them to create the best possible radiation treatments together”, says Pierre Fau, PhD, Head of the Medical Physics Department at IPC. Doctor Michel Resbeut, Head of the Radiotherapy Department of IPC, adds: “This cooperation illustrates a global innovation strategy in which our institute has been actively engaged for the last years”. “I am pleased to welcome Institut Paoli-Calmettes as a reference customer for RayStation® in France, says Johan Löf, CEO of RaySearch. “This is the beginning of a long-term cooperation and we are looking forward to working closely together to further improve the care for cancer patients.” About RayStation® RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability. About RaySearch RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm. For more information about RaySearch, visit www.raysearchlabs.com For further information, please contact: Johan Löf, President and CEO, RaySearch Laboratories AB Telephone: +46 (0)8-545 061 30 johan.lof@raysearchlabs.com



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us